Combination Therapies for the Treatment of Alzheimer's Disease and Related Disorders
The present invention relates to combination therapies for treating Alzheimer's disease or an amyloidosis-associated pathological condition comprising co-administering a therapeutically effective amount of a first compound, and a therapeutically effective amount of a second compound. In certain embodiments, the first compound or the second compound inhibits AB peptide polymerization; is an anti-inflammatory; improves cognitive function, mood, or social behavior; is associated with Tau or alpha-synuclein; or regulates amyloid peptide washout.
1 - 20 . (canceled)
21 . A method of treating a disease or condition in a subject in need thereof comprising co- administering a therapeutically effective amount of a first compound, and a therapeutically effective amount of a second compound, wherein the disease or condition is Alzheimer's disease, dementia, an amyloidosis-associated condition, or a head injury.
22 . A method of slowing the progression of a disease or condition in a subject in need thereof comprising co-administering a therapeutically effective amount of a first compound, and a therapeutically effective amount of a second compound, wherein the disease or condition is Alzheimer's disease, dementia, an amyloidosis-associated condition, or a head injury.
23 . The method of claim 21 , wherein the first compound and the second compound improve cognitive function, mood, or social behavior.
24 . The method of claim 22 , wherein the first compound and the second compound improve cognitive function, mood, or social behavior.
25 . The method of claim 23 , wherein the compound that improves cognitive function, mood, or social behavior is selected from the group consisting of a cholinesterase inhibitor, a N-methyl-D-aspartate (NMDA) receptor antagonist, an antioxidant, allopregnanolone, a tumor necrosis factor (TNF) inhibitor, spiro-(N′-methyl-piperidyl-4′)-N-ethyl-succinimide, latrepirdine, and R3487.
26 . The method of claim 25 , wherein the cholinesterase inhibitor is selected from the group consisting of donepezil, riastigmine and galantamine.
27 . The method of claim 25 , wherein the N-methyl-D-aspartate (NMDA) receptor antagonist is memantine.
28 . The method of claim 25 , wherein the antioxidant is either vitamin E or selegiline.
29 . The method of claim 25 , wherein the tumor necrosis factor (TNF) inhibitor is selected from the group consisting of etanercept, doxycycline, rifampin, and minocycline.
30 . The method of claim 24 , wherein the compound that improves cognitive function, mood, or social behavior is selected from the group consisting of a cholinesterase inhibitor, a N-methyl-D-aspartate (NMDA) receptor antagonist, an antioxidant, allopregnanolone, a tumor necrosis factor (TNF) inhibitor, spiro-(N′-methyl-piperidyl-4′)-N -ethyl-succinimide, latrepirdine, and R3487.
31 . The method of claim 30 , wherein the cholinesterase inhibitor is selected from the group consisting of donepezil, riastigmine and galantamine.
32 . The method of claim 30 , wherein the N-methyl-D-aspartate (NMDA) receptor antagonist is memantine.
33 . The method of claim 30 , wherein the antioxidant is either vitamin E or selegiline.
34 . The method of claim 30 , wherein the tumor necrosis factor (TNF) inhibitor is selected from the group consisting of etanercept, doxycycline, rifampin, and minocycline.